Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Award Type [Axis] Summary of significant accounting policies [Abstract] Accounts receivable Accounts Receivable, Net, Current Accounts payable Accounts Payable, Current Royalty provisions Accrued Royalties, Current Accrued expenses and other current liabilities Accumulated other comprehensive loss Weighted average amortization period Additional paid-in capital Accumulated Amortization [Abstract] Adjustments to reconcile to net cash provided by operating activities: All Other [Member] Amortization of debt issuance costs, net of tax Amortization of Financing Costs Amortization for intangible assets Amortization Amortization of Intangible Assets Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive shares excluded from calculation (in shares) Assets: Total assets Assets Current assets: ASSETS Assets [Abstract] Total current assets Assets, Current Total assets Assets, Fair Value Disclosure Prepaid expenses and other assets Accounts receivable Deferred taxes, net Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Business Acquisition [Axis] Business Acquisition, Pro Forma Information [Abstract] Price paid per share of acquisition (in dollars per share) Cash Pro Forma Information Contingent purchase consideration Business Combination, Contingent Consideration, Liability Acquired intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Acquisition [Line Items] Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Pro forma revenue Business Acquisition, Acquiree [Domain] Pro forma net income Acquisitions [Abstract] Transaction costs Total purchase price Intangible Assets Acquired [Abstract] Inventory Acquisitions Property, plant and equipment Total fair value of tangible assets acquired and liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Inception to date transaction costs Net loss attributable to Emergent BioSolutions Inc. Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Recognized revenues Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Estimated Purchase Price [Abstract] Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Investment in money market funds (1) Cash and Cash Equivalents, Fair Value Disclosure Variable Interest Entity, Classification [Domain] Commitments and contingencies Common stock, par value (in dollars per share) Common stock, $0.001 par value; 100,000,000 shares authorized, 37,719,153 shares issued and 37,306,200 shares outstanding at March 31, 2014; 37,036,996 shares issued and 36,624,043 shares outstanding at December 31, 2013 Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock, shares outstanding (in shares) Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Basis of presentation and consolidation Contracts and grants Contract Manufacturing [Member] Contractual Rights [Member] Cost of product sales and contract manufacturing Cost of Goods Sold Contract Manufacturing [Member] Long-Term Debt [Line Items] Debt Instrument [Line Items] Schedule of Long-term Debt Instruments [Table] Face amount of debt instrument Long-term debt Debt and Capital Leases Disclosures [Text Block] Long-term debt [Abstract] Conversion price per share (in dollars per share) Debt issuance costs Interest rate, stated percentage (in hundredths) Maturity date Current and deferred income taxes Deferred revenue, current portion Deferred revenue, net of current portion Deferred tax assets, net Deferred Tax Assets, Net of Valuation Allowance, Current Deferred tax assets, net Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred tax liability, net Deferred tax liability, current portion (net) Depreciation and amortization Equity awards Equity awards [Abstract] Earnings per share Earnings Per Share [Text Block] Loss per share - basic (in dollars per share) Income per share-basic (in dollars per share) Loss per share - diluted (in dollars per share) Income per share-diluted (in dollars per share) Earnings per share [Abstract] Effect of exchange rate changes on cash and cash equivalents Accrued compensation Employee-related Liabilities, Current Convertible debt [Member] Excess tax benefits from stock-based compensation Excess Tax Benefit from Share-based Compensation, Operating Activities Excess tax benefits from stock-based compensation Additions Fair Value by Measurement Frequency [Axis] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Hierarchy [Axis] Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Present value discount rate (in hundredths) Fair Value, Measurements, Recurring [Member] Fair Value, Measurement Frequency [Domain] Transfers in/(out) of Level 3 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Balance, end of period Balance, beginning of period Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Fair value measurements [Abstract] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair value measurements Fair Value Disclosures [Text Block] Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Unobservable Input Reconciliation [Roll Forward] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Expense (income) included in earnings Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life Intangible Assets, Beginning Balance Intangible Assets, Ending Balance Finite-Lived Intangible Assets, Gross Accumulated Amortization, Beginning Balance Accumulated Amortization, Ending Balance Finite-Lived Intangible Assets, Accumulated Amortization Net book value of intangible assets Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Goodwill Goodwill, net book value Intangible assets, in-process research and development and goodwill Goodwill [Roll Forward] Goodwill, Beginning Balance Goodwill, Ending Balance Goodwill, Gross Intangible assets, in-process research and development and goodwill [Abstract] Goodwill, Additions Goodwill, Acquired During Period Consolidated Statements of Operations (unaudited) [Abstract] Loss before benefit for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Income Statement Location [Axis] Income Statement Location [Domain] Benefit from income taxes Income tax receivable, net Income tax receivable, long-term Income Taxes Receivable, Noncurrent Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable Accrued expenses and other liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Changes in operating assets and liabilities: Inventories Increase (Decrease) in Inventories Accrued compensation Income taxes Increase (Decrease) in Income Taxes Receivable Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Dilutive securities-equity awards (in shares) Intangible Assets [Abstract] Intangible assets, net Cost Basis [Abstract] Interest expense Interest Expense Interest expense applicable to convertible debt, net of tax Interest on Convertible Debt, Net of Tax Total inventories Inventories Inventory, Net Finished goods Inventories Inventory Disclosure [Text Block] Raw materials and supplies Inventories Inventory, Policy [Policy Text Block] Step up adjustment to inventory Inventories [Abstract] Work-in-process Interest income Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Total current liabilities Liabilities, Current Total liabilities and stockholders' equity Liabilities and Equity Current liabilities: Total liabilities Liabilities LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities: Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Licensed Products [Member] Licensed Products [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Long-term indebtedness, net of current portion Long-term Debt, Excluding Current Maturities Marketed Products [Member] Marketing-Related Intangible Assets [Member] Maximum [Member] Minimum [Member] Variable interest entities Noncontrolling Interest Disclosure [Text Block] Noncontrolling interest in subsidiaries Cash flows from financing activities: Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Cash flows from investing activities: Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from operating activities: Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net loss attributable to Emergent BioSolutions Inc. Net loss attributable to Emergent BioSolutions Inc. Net income (loss) Net loss Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Total other income (expense) Nonoperating Income (Expense) Other income (expense): Number of business segments Variable interest entities [Abstract] Operating expenses: Loss from operations Operating Income (Loss) Adjustment to noncontrolling interest Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Foreign currency translations, net of tax Other assets Other Other Noncash Income (Expense) Non-cash development expenses from joint venture Other income (expense), net Other liabilities Acquisition of Cangene Corporation Payments to Acquire Businesses, Net of Cash Acquired Amount of cash paid to Bracco Diagnostics, Inc. Payments to Acquire Businesses, Gross Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Plan Name [Domain] Plan Name [Axis] Preferred stock, par value (in dollars per share) Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively Preferred stock, shares issued (in shares) Preferred stock, shares authorized (in shares) Preferred stock, shares outstanding (in shares) Prepaid expenses and other current assets Proceeds from convertible debenture, net of debt issuance costs Proceeds from Convertible Debt Proceeds from other long-term debt obligations Issuance of common stock subject to exercise of stock options Net loss Net loss Property, plant and equipment, net Range [Axis] Range [Domain] Principal payments on long-term indebtedness Payments on borrowings on long-term indebtedness Repayments of Long-term Debt Research and development Restricted Stock Units (RSUs) [Member] Retained earnings Revenue recognition External revenue Subsegments [Axis] Subsegments [Domain] Exercisable, end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Product sales Total revenues Revenue, Net Revenues: Purchase Price Allocation Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Purchase Price Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Option Award Activity Intangible Assets Inventories Schedule of Inventory, Current [Table Text Block] Restricted Stock Units Activity Summary of Basic and Diluted Net Income per Share Schedule of Business Acquisitions, by Acquisition [Table] Goodwill Schedule of Goodwill [Table Text Block] Fair Value of Intangible Assets Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Variable Interest Entities [Table] Segment Reporting Information [Line Items] Segments [Domain] Segment [Domain] Segment information [Abstract] Segment information Segment Reporting Disclosure [Text Block] Selling, General and Administrative Expenses [Member] Selling, general and administrative Selling, General and Administrative Expense Aggregate intrinsic value [Abstract] Restricted stock unit award activity [Roll Forward] Weighted-Average Exercise Price [Roll Forward] Granted (in shares) Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Outstanding, end of period (in shares) Outstanding, beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Stock-based compensation expense Weighted-Average Grant Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Outstanding, end of period (in dollars per share) Outstanding, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Exercised (in dollars per share) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Exercisable, end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Exercisable, end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Forfeited (in dollars per share) Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Outstanding, end of period (in dollars per share) Outstanding, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, end of period (in shares) Outstanding, beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, end of period Outstanding, beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options outstanding [Roll Forward] Award Type [Domain] Summary of significant accounting policies Significant Accounting Policies [Text Block] Consolidated Statements of Cash Flows (Unaudited) [Abstract] Consolidated Statements of Comprehensive Loss (Unaudited) [Abstract] Consolidated Balance Sheets (unaudited) [Abstract] Segments [Axis] Statement, Business Segments [Axis] Stock Options [Member] Stock Compensation Plan [Member] Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Stockholders' equity: Total Emergent BioSolutions Inc. stockholders' equity Stockholders' Equity Attributable to Parent Total stockholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Corporate Tradename [Member] Corporate Trade Name [Member] Treasury stock (in shares) Treasury stock, at cost, 412,953 common shares at March 31, 2014 and December 31, 2013 Treasury Stock, Value Variable Interest Entities by Classification of Entity [Axis] Variable Interest Entity [Line Items] Net losses included in the Company's consolidated statement of operations Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted-average number of shares - basic (in shares) Weighted-average number of shares-basic (in shares) Weighted-average number of shares - diluted (in shares) Weighted-average number of shares-diluted (in shares) Credit agreement dated December 2013. Credit Agreement [Member] Maximum leverage ratio required to be maintained under a debt covenant agreement. A leverage ratio is calculated by dividing the funded debt by earnings before interest, taxes, depreciation and amortization for the most recent four quarters. Debt Instrument, covenant, leverage ratio Debt covenant, leverage ratio, maximum Maximum senior leverage ratio required to be maintained under a debt covenant agreement. A leverage ratio is calculated by dividing the funded debt by earnings before interest, taxes, depreciation and amortization for the most recent four quarters. Debt Instrument, covenant, senior leverage ratio Debt Instrument, covenant, senior leverage ratio, maximum Number of lending institutions in which the entity has a credit facility. Number of lending institutions A debt coverage ration required to be maintained under a debt covenant agreement. The debt coverage ratio is calculated by dividing earnings before interest, taxes, depreciation and amortization for the most recent four quarters less cash taxes by the sum of current obligations and interest expense for borrowed money, in each case due and payable following four quarters. Debt Instrument, covenant, debt coverage ratio Debt covenant, consolidated debt service coverage ratio, minimum Minimum cash and liquid investments balance required in order to be in compliance with the covenant clauses of the debt agreement. Debt instrument covenant, minimum cash and liquid investments balance Debt covenant, minimum cash and liquid investments balance The cash inflow from a contractual arrangement with the lender, including line of credit and long-term indebtednesses, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. Proceeds From Borrowings On Long Term Indebtness And Line Of Credit Proceeds from borrowings on long-term indebtedness The amount of project costs to be expended at Montgomery County Site. Project costs to be expended at Montgomery County Site Project costs to be expended at Montgomery County Site Loan obtained from State of Maryland and Montgomery County. State of Maryland and Montgomery County [Member] State of Maryland and Montgomery County [Member] BAML Term Loan EBS BAML Term Loan [Member] BAML Term Loan [Member] Debt instrument dated January 2014 due 2021. Convertible Senior Notes Due 2021 [Member] 2.875% Convertible Senior Notes Due 2021 [Member] Revolving credit loan dated in December 2013. Revolving Credit Loan dated December 2013, due in December 2018 [Member] BAML Revolving Credit Facility [Member] The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. Debt Instrument, Number of Equity Instruments Conversion rate of notes per $1,000 principal amount (in shares) Document and Entity Information [Abstract] The portion of profit or loss for the period, net of income taxes and other adjustments. Adjusted net loss Adjusted net loss Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts. In process research and development Carrying value as of the balance sheet date of the current portion of liabilities incurred and payable to former shareholders and stock option holders of Trubion Pharmaceuticals for certain developmental, regulatory or commercial milestones. Contingent Value Rights Current Portion Contingent purchase consideration, current portion Carrying value as of the balance sheet date of the noncurrent portion of liabilities incurred and payable to former shareholders and stock option holders of Trubion Pharmaceuticals for certain developmental, regulatory or commercial milestones. Contingent Value Rights Net Of Current Portion Contingent purchase consideration, net of current portion Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the non current portion of the liabilities. Accrued Royalties, Non Current Royalty provisions, net of current portion Current portion of the carrying values as of the balance sheet date of obligations incurred through that date and payable for chargebacks. Provision for chargebacks The cash outflow for contingent value rights. Contingent value right payment Contingent obligation payments Write-off of amounts previously recorded bank fees. Write off of bank fees Write off of bank fees The provision charged to earnings in the period related to chargebacks obligations. Provision for chargebacks, charged to earnings Provision for chargebacks Number of business units under the entities reporting segments. Number of business units A components of the Biosciences business segment. IXinity product candidates [Member] IXinity product candidates [Member] A components of the Biosciences business segment. Otlertuzumab [Member] Otlertuzumab [Member] Goodwill, Cost Basis [Abstract] A components of the Biosciences business segment. Biosciences Therapeutics [Member] Marketed products classified as intangible assets. Marketed Products [Member] Marketed Products [Member] Segment of the Company which develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism or biowarfare. Biodefense [Member] Biodefense products classified as intangible assets. Biodefense Products [Member] Biodefense Products [Member] Revenue earned during the period arising from manufacturing sale under the terms of a contract. Contract manufacturing Contract manufacturing A share-based compensation plan adopted by the Company in 2006. Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member] 2006 Plan [Member] A share-based compensation plan adopted by the Company in 2004. Emergent BioSolutions Employee Stock Option Plan [Member] 2004 Plan [Member] An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentives employees, in addition to their regular salary and other benefits. us-gaap_ Convertible Debt [Member] Convertible debt [Member] The intrinsic value of non vested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units. Share Based Compensation Arrangement, Equity Instruments other than Options, Outstanding, Aggregate Intrinsic value Outstanding, beginning of period Outstanding, end of period An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentives employees, in addition to their regular salary and other benefits. Stock Options Member [Member] Amount of purchases, sales, and issues in relation to liabilities measured at fair value on a recurring basis using unobservable inputs (level 3). Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues Purchases, sales and issuances This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents a type of right given to shareholders of an acquired company (or a company facing major restructuring) that ensures they receive additional benefit if a specified event occurs. Contingent Value Rights, Fair Value Disclosure Contingent purchase consideration This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents obligations incurred through that date and payable for royalties. Royalty provisions, Fair Value Disclosure Royalty provisions Fair value measurement of contingent value rights granted to former shareholders and stock option holders of Bracco Diagnostics Inc. for net sales of RSDL Change In Fair Value Of Contingent Obligations Change in fair value of contingent obligations Rights to biodefense. Biodefense Intangible Asset [Member] Biodefense [Member] Business acquisition in February 2014. Cangene [Member] Amount of in-process research and development acquired at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, In-process research and development Acquired in-process research and development Describes the periods of time over which an entity anticipates to receive utility from its inventory (that is, the periods of time over which an entity allocates the increase in value of acquired inventory). Amortization period of step up adjustment Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. acquired at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Income tax receivable Income tax receivable Amount of liability recognized arising from royalty provision in a business combination. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Royalty Provision Contingent consideration Amount of liability recognized arising from provision for chargebacks in a business combination. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Provision for Chargebacks Provision for chargebacks Amount of current accrued liabilities incurred for goods and services received. us-gaap_ Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Accrued Liabilities Accrued liabilities and Accounts Payable RSDL, a product of HPPD. RSDL [Member] Manufacturing agreement designated as an intangible asset. Manufacturing Agreement [Member] HPPD a division of Bracco. HPPD [Member] Contingent consideration measured by net sales of a product. Contingent Consideration Percentage Of Net Sales Contingent consideration, percentage of RSDL net sales (in hundredths) The number of basic criteria required for the Company to recognize revenues from product sales. Basic criteria for revenue recognition Segment of the Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs. Biosciences [Member] Represents a Variable Interest Entity in which the company is primary beneficiary. A collaborative arrangement with the University of Oxford ("Oxford") and certain University of Oxford researchers to conduct clinical trials in the advancement of a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC"). Oxford Emergent Tuberculosis Consortium [Member]